- Home
- Equipment
- usa new york
- oncology
Refine by
Oncology Equipment Supplied In Usa New York
31 equipment items found
Manufactured by:POP Biotechnologies, Inc. (POP BIO) based inBuffalo, NEW YORK (USA)
PhotoDOX is a revolutionary cancer therapy designed to address solid tumors which are resistant to current standards of care through the innovative benefits of the light-activated PoP-liposome drug delivery ...
Manufactured by:Keller Technology Corporation (KTC) based inTonawanda, NEW YORK (USA)
For the radio oncology and medical imaging industries, particle and photon beam delivery are essential components in many of the most sophisticated machines and equipment. From medical research to therapeutics to diagnostics, accelerator technology powers a wide range of modern health care applications. ...
Manufactured by:Keller Technology Corporation (KTC) based inTonawanda, NEW YORK (USA)
Keller provides medical device and equipment manufacturing for imaging and radio oncology including proton therapy, linac delivered radiotherapy, PET and MRI. We bring expertise in cGMP regulatory environments. Projects include accelerator, cyclotron and magnet-based equipment for imaging or therapeutic ...
Manufactured by:UroGen Pharma, Inc. based inPrinceton, NEW YORK (USA)
UroGen is evaluating UGN-301, our in-licensed anti-CTLA-4 antibody (zalifrelimab), as a monotherapy and as combination therapy with ...
Manufactured by:ENB Therapeutics based inNew York, NEW YORK (USA)
ETBR on the luminal surface of tumor blood vessels, creates a barrier to transendothelial migration and homing of T-cells from the vessel to the tumor by downregulating ICAM-1 (an adhesion molecule). ETBRI blockers restore ICAM-1 expression which is required for T-cells to leave the circulation and infiltrate the tumor. Activated T cells are then able to infiltrate the tumor and kill ...
Manufactured by:Zetagen Therapeutics Inc. based inSyracuse, NEW YORK (USA)
ZetaMet is a synthetic, small-molecule, inductive biologic technology being developed to target and resolve metastatic bone lesions while inhibiting future tumor growth and regenerating bone. The small molecule has been approved by the U.S. Food and Drug Administration (FDA) since 1971. Zetagen scientists have discovered an entirely new pathway for this established molecule which, if proven ...
Manufactured by:Zetagen Therapeutics Inc. based inSyracuse, NEW YORK (USA)
ZetaMet Settable is being designed for the treatment of patients with metastatic lesions that have or will result in a Skeletal-Related Event, (SRE) including fractures and spinal cord ...
Manufactured by:Allied Motion, Inc. based inAmherst, NEW YORK (USA)
Allied Motion offers housed direct drive brushless torque motors ready to mount into your application. These high performance motors are available in four series with outer diameters up to 170 mm (6.7 in). The CM series are available with eight different optical encoder versions, including absolute formats. Our housed Megaflux series are fully integrated units that include a servo drive and an ...
Manufactured by:Allied Motion, Inc. based inAmherst, NEW YORK (USA)
Allied Motion is a technology leader in Frameless Brushless Direct Drive Torque Motors. Allied has developed and manufactures several types of frameless direct drive brushless motors, including a broad range of standard catalog models. Allied is also well-known for the special and completely custom torque motors we have developed. Key characteristics of each family of frameless brushless direct ...
Manufactured by:United Biomedical based inNew York, NEW YORK (USA)
Development and manufacture of large proteins and mAbs for human indications, including HIV/AIDS and ...
Manufactured by:Celyad Oncology based inMont-Saint-Guibert, BELGIUM
The expression of TIM reduces signaling of the TCR complex by interfering with the CD3ζ component of the TCR complex. Celyad Oncology plans to initiate the KEYNOTE-B79 trial to evaluate CYAD-101 with Merck’s anti-PD1 therapy, KEYTRUDA (pembrolizumab), in refractory mCRC patients with microsatellite stable / mismatch-repair proficient disease during the fourth ...
Manufactured by:AngioDynamics, Inc. based inLatham, NEW YORK (USA)
The IsoLoc Endorectal Balloon’s unique, customer-driven design is the result of collaborations with Radiation Oncologists, Therapists and Physicists with one goal in mind – to create a new standard for endorectal balloons (ERB) in the oncology ...
Manufactured by:Delta Med based inViadana, ITALY
Totally transparent to assist blood draws, it supports up to 600 activations guaranteed for 7 days. The valve is light and flat, with a swabable surface, and is suitable for neonatal infusions and oncology (flow rates 160ml per ...
Manufactured by:Regeneron Pharmaceuticals Inc. based inTarrytown, NEW YORK (USA)
elociT™ is our unique mouse technology for producing fully human therapeutic T-cell receptors (TCR) against tumor and viral antigens. Regeneron uses this technology as part of its efforts to discover and develop novel immuno-oncology therapeutic candidates, including combination approaches and to assist our collaborators in producing fully human therapeutic ...
by:Hookipa Pharma Inc. based inVienna, AUSTRIA
Our replicating technology is designed to create a stronger immune response that we believe is more appropriate for use in oncology. Our non-replicating technology is designed to evoke a potent immune response for prophylactic use against infectious disease. ...
Manufactured by:Cutting Edge Laser Technologies based inRochester, NEW YORK (USA)
Because of its low-invasive nature, clients can expect increased efficiency, safety and reduction of healing time, all leading to higher customer compliance. A wide range of fibers (200-365-550-600-1000) makes this an ideal tool for neurology, orthopedics, urology and oncology. Its software can store up to 30 operating protocols. Technical Simplicity and LCD display makes ...
Manufactured by:Celyad Oncology based inMont-Saint-Guibert, BELGIUM
CYAD-221 is a preclinical short hairpin RNA (shRNA)-based allogeneic CAR T candidate for the treatment of B-cell malignancies. CYAD-221 is engineered to co-express a CD19 chimeric antigen receptor and an shRNA hairpin which interferes with the expression of the CD3ζ component of the TCR ...
Manufactured by:Celyad Oncology based inMont-Saint-Guibert, BELGIUM
CYAD-02 is an investigational CAR T therapy that engineers an all-in-one vector approach in patient’s T cells to express both (i) the NKG2D chimeric antigen receptor, a receptor expressed on natural killer (NK) cells that binds to eight stress-induced ligands (NKG2DL) expressed on tumor cells, and (ii) short hairpin RNA (shRNA) technology to knockdown the expression of NKG2D ligands MICA ...
Manufactured by:Celyad Oncology based inMont-Saint-Guibert, BELGIUM
CYAD-231 is a dual specific CAR T candidate targeting NKG2D and an undisclosed membrane protein. The short hairpin RNA (shRNA)-based allogeneic CAR T candidate is in preclinical ...
Manufactured by:Celyad Oncology based inMont-Saint-Guibert, BELGIUM
CYAD-211 is a short hairpin RNA (shRNA)-based allogeneic CAR T candidate for the treatment of relapsed or refractory multiple myeloma (r/r MM). CYAD-211 is engineered to co-express a B-cell maturation antigen (BCMA) chimeric antigen receptor and a single shRNA hairpin which interferes with the expression of the CD3ζ component of the TCR complex. CYAD-211 is currently being evaluated, ...